Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Scheifele

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Pediatrics|July 20, 2011
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 monthsDanuta M Skowronski, Travis S Hottes, Mei Chong, et al.
Clinical and Vaccine Immunology : CVI|May 24, 2013
Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network StudyMona Al-Dabbagh, Keswadee Lapphra, David W Scheifele, et al.
Pediatrics|September 5, 2006
Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004Dorothy L Moore, Wendy Vaudry, David W Scheifele, et al.
The Journal of Infectious Diseases|August 9, 2012
Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v)Danuta M Skowronski, Naveed Z Janjua, Gaston De Serres, et al.
The Lancet. Infectious Diseases|April 24, 2017
Maternal immunisation: collaborating with mother natureArnaud Marchant, Manish Sadarangani, Mathieu Garand, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparisonDavid W Scheifele, Shelly A McNeil, Brian J Ward, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2019
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical TrialRobine Donken, Simon R M Dobson, Kim D Marty, et al.
The Journal of General Virology|February 16, 2006
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirusRaymond H See, Alexander N Zakhartchouk, Martin Petric, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Pediatrics|July 20, 2011
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 monthsDanuta M Skowronski, Travis S Hottes, Mei Chong, et al.
Clinical and Vaccine Immunology : CVI|May 24, 2013
Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network StudyMona Al-Dabbagh, Keswadee Lapphra, David W Scheifele, et al.
Pediatrics|September 5, 2006
Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004Dorothy L Moore, Wendy Vaudry, David W Scheifele, et al.
The Journal of Infectious Diseases|August 9, 2012
Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v)Danuta M Skowronski, Naveed Z Janjua, Gaston De Serres, et al.
The Lancet. Infectious Diseases|April 24, 2017
Maternal immunisation: collaborating with mother natureArnaud Marchant, Manish Sadarangani, Mathieu Garand, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparisonDavid W Scheifele, Shelly A McNeil, Brian J Ward, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2019
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical TrialRobine Donken, Simon R M Dobson, Kim D Marty, et al.
The Journal of General Virology|February 16, 2006
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirusRaymond H See, Alexander N Zakhartchouk, Martin Petric, et al.
Pageof 8